Bioxyne Ltd
BXN
Company Profile
Business description
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
Contact
50 Clarence Street
Suite 506, Level 5
SydneyNSW2000
AUST: +61 290787669
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
30 June 2026
Employees
16
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,276.60 | 19.90 | -0.21% |
| CAC 40 | 8,041.36 | 18.77 | -0.23% |
| DAX 40 | 24,611.25 | 14.12 | 0.06% |
| Dow JONES (US) | 46,449.37 | 152.41 | -0.33% |
| FTSE 100 | 9,509.40 | 39.47 | -0.41% |
| HKSE | 26,752.59 | 76.87 | -0.29% |
| NASDAQ | 23,001.26 | 42.12 | -0.18% |
| Nikkei 225 | 48,580.44 | 845.45 | 1.77% |
| NZX 50 Index | 13,570.86 | 2.38 | 0.02% |
| S&P 500 | 6,736.77 | 16.95 | -0.25% |
| S&P/ASX 200 | 8,969.80 | 25.20 | -0.28% |
| SSE Composite Index | 3,933.97 | 51.20 | 1.32% |